# Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

> **NCT03713593** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 794 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** lenvatinib
- **BIOLOGICAL:** pembrolizumab
- **DRUG:** saline placebo

## Key facts

- **NCT ID:** NCT03713593
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-31
- **Primary completion:** 2022-06-21
- **Final completion:** 2024-09-24
- **Target enrollment:** 794 (ACTUAL)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03713593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03713593, "Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03713593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*